Dexamethasone Intravitreal implant

BNF:: 11.4.1
Status:: Red
Decision Date:: August 2011

Comments

RED:

NICE TA229: recommended for specified people with macular oedema secondary to retinal vein occlusion. (Decision date - August 2011).
NICE TA349: for diabetic macular oedema. (Decision date - August 2015).
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis. (Decision date - August 2017).
NICE TA824: Dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema. (Decision date - October 2022).

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)